Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of MTX-463 in idiopathic pulmonary fibrosis
NL-OMON60007Phase 2Active, not recruiting
- Sponsor
- Mediar Therapeutics
- Start
- Feb 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of MTX-463 in idiopathic pulmonary fibrosis (IPF), sponsored by Mediar Therapeutics. Started Feb 2026; status: active, not recruiting.
02
Drugs
MTX-463
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NL-OMON60007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60007.